Related Experiment Video
Updated: Aug 7, 2026
Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells
Published on: February 2, 2024
Morphological and functional characterization of a pancreatic beta-cell line microencapsulated in sodium cellulose
V Stadlbauer1, P B Stiegler, S Schaffellner
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria. vanessa.stadlbauer@meduni-graz.at
Background:
Late diabetic complications cannot be prevented totally by current antidiabetic strategies. Therefore, new therapeutic concepts of insulin replacement such as pancreas transplantation are evolving. Due to the shortage of human donor organs, transplantation of microencapsulated xenogeneic pancreatic islet cells has attracted considerable attention. Sodium cellulose sulfate/poly(diallyldimethylammonium chloride) (NaCS/PDADMAC) is a material with favorable biogenic properties that has been used for microencapsulation of various cell types. However, there are no data on the suitability of NaCS/PDADMAC for microencapsulation of pancreatic beta-cells.
Material And Methods:
Cell growth and viability of NaCS/PDADMAC-microencapsulated HIT-T15 cells, an immortalized hamster pancreatic beta-cell line, were assessed using a dimethylthiazol-diphenyltetrazoliumbromide (MTT)-based cell growth determination kit and apoptosis was detected by antibodies against activated caspase 3. Glucose-dependent insulin secretion was assessed with ELISA and the uptake of glucose was measured using fluorescence-labeled glucose.
Results:
Statistical analysis revealed no differences in glucose-dependent cell proliferation, insulin secretion and glucose uptake between non-microencapsulated and microencapsulated HIT-T15 cells. Stimulation of HIT-T15 cells with glucose (100 mg/ml) resulted in a biphasic insulin secretion response.
Conclusion:
Microencapsulation of HIT-T15 cells in NaCS/PDADMAC does not influence cell proliferation, insulin secretion and glucose uptake. Our results indicate that NaCS/PDADMAC is well suited for microencapsulation of pancreatic beta-cells.
Insights
Microencapsulation using Sodium cellulose sulfate/poly(diallyldimethylammonium chloride) (NaCS/PDADMAC) effectively preserves pancreatic beta-cell function. This technique supports cell proliferation, insulin secretion, and glucose uptake, showing promise for diabetes treatment.
Area of Science:
- Biomaterials Science
- Cell Encapsulation Technology
- Diabetes Research
Background:
- Current diabetes management strategies are insufficient for preventing late complications.
- Pancreas transplantation is an evolving therapeutic concept for insulin replacement.
- Xenogeneic pancreatic islet cell transplantation faces donor organ shortages, driving interest in microencapsulation.
Purpose of the Study:
- To evaluate the suitability of Sodium cellulose sulfate/poly(diallyldimethylammonium chloride) (NaCS/PDADMAC) for microencapsulating pancreatic beta-cells.
- To assess the impact of NaCS/PDADMAC microencapsulation on HIT-T15 cell viability, proliferation, and function.
Main Methods:
- HIT-T15 cells (immortalized hamster pancreatic beta-cell line) were microencapsulated using NaCS/PDADMAC.
- Cell growth and viability were assessed using MTT assays.
- Apoptosis was detected via activated caspase 3 antibodies; glucose-dependent insulin secretion and glucose uptake were measured.
Main Results:
- No significant differences were observed in glucose-dependent cell proliferation between microencapsulated and non-microencapsulated HIT-T15 cells.
- Insulin secretion and glucose uptake remained unaffected by NaCS/PDADMAC microencapsulation.
- A biphasic insulin secretion response was noted upon glucose stimulation (100 mg/ml).
Conclusions:
- NaCS/PDADMAC microencapsulation does not adversely affect pancreatic beta-cell proliferation, insulin secretion, or glucose uptake.
- The findings suggest NaCS/PDADMAC is a suitable biomaterial for pancreatic beta-cell microencapsulation.
- This technique holds potential for future diabetes therapeutic strategies involving cell replacement.